TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07310290: Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks

Sponsor: AbbVie · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 189 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$12,416,000

Rescue Site Savings

+$8,186,800

Unlock Full NCT07310290 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07310290 Rescue Dossier →